Second Sight Medical Products Inc. Announces Resumption of Its Early Feasibility Study of the Orion® Cortical Visual Prosthe...
September 22 2020 - 8:00AM
Business Wire
Second Sight Medical Products Inc. (NASDAQ: EYES), a developer,
manufacturer and marketer of implantable visual prosthetics that
are intended to create an artificial form of useful vision for
blind individuals, today announced the resumption of its Early
Feasibility Study of the Orion® Visual Cortical Prosthesis System
(“Orion”) at UCLA Medical Center (“UCLA”). The study, which
includes four participants at UCLA and two participants at Baylor
College of Medicine (“Baylor”), was paused for in-person visits
following the guidelines for clinical trials at each institution in
March 2020 due to COVID-19. Study visits have now been resumed;
several UCLA participants are being examined this week, and Baylor
is anticipated to resume its study soon.
The first human subject was implanted with Orion in January
2018. A total of six subjects have been implanted in the Orion
Early Feasibility Study.
“We are delighted that the Early Feasibility Study has
restarted. The study, like many such investigations, was suspended
as medical centers focused attention and resources on their
COVID-19 response and to protect the health of study participants.
Our highest priority remains the health and safety of all of our
study participants, and we look forward to continuing this
important research. We remain committed to this innovative
technology and believe that Orion has the potential to safely
benefit blind individuals and help them to perform everyday tasks,”
stated Matt Pfeffer, Acting Chief Executive Officer.
Orion is a breakthrough technology intended to provide useful
artificial vision to individuals who are blind due to a wide range
of causes, including glaucoma, diabetic retinopathy, optic nerve
injury or disease, and eye injury. Orion converts images captured
by a miniature video camera mounted on glasses into a series of
small electrical pulses transmitted wirelessly to electrodes
implanted directly on the visual cortex of the individual subject’s
brain.
In June 2019, the study’s principal investigators, Nader
Pouratian, MD, Ph.D. of UCLA and Daniel Yoshor, MD of Baylor,
presented 12-month results from the Early Feasibility Study at the
World Society for Stereotactic and Functional Neurosurgery Annual
Meeting in New York City. On both the primary and secondary outcome
measures, latest results at 12 months have been positive.
Safe Harbor
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are intended to be covered by the “safe harbor”
created by those sections. All statements in this release that are
not based on historical fact are “forward looking statements.”
These statements may be identified by words such as “estimates,”
“anticipates,” “projects,” “plans,” “strategy,” “goal,” or
“planned,” “seeks,” “may,” “will,” “expects,” “intends,”
“believes,” “should,” and similar expressions, or the negative
versions thereof, and which also may be identified by their
context. All statements that address operating performance or
events or developments that Second Sight expects or anticipates
will occur in the future, such as stated objectives or goals, our
refinement of strategy, including the outcome of our announced
downgrading of operations, our attempts to secure additional
financing, our exploring possible business alternatives, or that
are not otherwise historical facts, are forward-looking statements.
While management has based any forward-looking statements included
in this release on its current expectations, the information on
which such expectations were based may change. Forward-looking
statements involve inherent risks and uncertainties which could
cause actual results to differ materially from those in the
forward-looking statements as a result of various factors,
including those risks and uncertainties described in or implied by
the Risk Factors and in Management’s Discussion and Analysis of
Financial Condition and Results of Operations sections of our
Annual Report on Form 10-K, filed on March 19, 2020 and Forms 10-Q
filed June 26, 2020 and August 13, 2020, and our other reports
filed from time to time with the Securities and Exchange
Commission. We urge you to consider those risks and uncertainties
in evaluating our forward-looking statements. We caution readers
not to place undue reliance upon any such forward-looking
statements, which speak only as of the date made. Except as
otherwise required by the federal securities laws, we disclaim any
obligation or undertaking to publicly release any updates or
revisions to any forward-looking statement contained herein (or
elsewhere) to reflect any change in our expectations with regard
thereto, or any change in events, conditions, or circumstances on
which any such statement is based.
About Second Sight Medical Products Inc.
Second Sight Medical Products, Inc. (NASDAQ: EYES) develops,
manufactures and markets implantable visual prosthetics that are
intended to deliver useful artificial vision to blind individuals.
A recognized global leader in neuromodulation devices for
blindness, the Company is committed to developing new technologies
to treat the broadest population of sight-impaired individuals. The
Company’s headquarters are in Los Angeles, California. More
information is available at https://secondsight.com.
About the Orion Visual Cortical Prosthesis System
Leveraging Second Sight’s 20 years of experience in
neuromodulation for vision, the Orion Visual Cortical Prosthesis
System (Orion) is an implanted cortical stimulation device intended
to provide useful artificial vision to individuals who are blind
due to a wide range of causes, including glaucoma, diabetic
retinopathy, optic nerve injury or disease, and eye injury. Orion
is intended to convert images captured by a miniature video camera
mounted on glasses into a series of small electrical pulses. The
device is designed to bypass diseased or injured eye anatomy and to
transmit these electrical pulses wirelessly to an array of
electrodes implanted on the surface of the brain’s visual cortex,
where it is intended to provide the perception of patterns of
light. A six-subject early feasibility study of the Orion is
currently underway at the Ronald Reagan UCLA Medical Center in Los
Angeles and the Baylor College of Medicine in Houston. No
peer-reviewed data is available yet for the Orion system.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200922005548/en/
Investor Relations In-Site Communications, Inc. Lisa
Wilson, President T: 212-452-2793 E: lwilson@insitecony.com
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Mar 2024 to Apr 2024
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Apr 2023 to Apr 2024